Home » Stocks » MITO

Stealth BioTherapeutics Corp. (MITO)

Stock Price: $1.72 USD -0.07 (-3.91%)
Updated Jan 26, 2021 1:23 PM EST - Market open
Market Cap 89.31M
Revenue (ttm) 21.09M
Net Income (ttm) -71.73M
Shares Out 375.67M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $1.72
Previous Close $1.79
Change ($) -0.07
Change (%) -3.91%
Day's Open 1.80
Day's Range 1.70 - 1.82
Day's Volume 375,328
52-Week Range 0.97 - 3.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 weeks ago

BOSTON, Jan. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel th...

PRNewsWire - 2 weeks ago

BOSTON, Jan. 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel th...

PRNewsWire - 1 month ago

BOSTON, Dec. 9, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel th...

PRNewsWire - 2 months ago

BOSTON, Nov. 24, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and...

Seeking Alpha - 2 months ago

Stealth BioTherapeutics (MITO) CEO Reenie McCarthy on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

BOSTON, Nov. 5, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel th...

PRNewsWire - 2 months ago

BOSTON, Nov. 4, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel th...

PRNewsWire - 2 months ago

BOSTON, Oct. 30, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel t...

PRNewsWire - 3 months ago

BOSTON, Oct. 19, 2020 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therap...

PRNewsWire - 4 months ago

BOSTON, Sept. 23, 2020 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel thera...

PRNewsWire - 4 months ago

BOSTON, Sept. 10, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel ...

Seeking Alpha - 5 months ago

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q2 2020 Earnings Call Transcript

PRNewsWire - 7 months ago

BOSTON, May 26, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel th...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).

Seeking Alpha - 8 months ago

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 9 months ago

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q4 2019 Results - Earnings Call Transcript

24/7 Wall Street - 10 months ago

Stealth BioTherapeutics Corp. (NASDAQ: MITO) stock more than doubled on Tuesday after the company announced a critical update from the U.S.

Market Watch - 1 year ago

Shares of Stealth BioTherapeutics MITO, -63.94% tumbled 63% after it said a late-stage trial for its investigational treatment of primary mitochondrial myopathy, a muscular disease caused by g...

24/7 Wall Street - 1 year ago

Stealth BioTherapeutics Corp. (NASDAQ: MITO) shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with primary mitochondrial myopathy.

About MITO

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead disc... [Read more...]

Industry
Biotechnology
IPO Date
Feb 15, 2019
CEO
Irene P. McCarthy J.D.
Employees
73
Stock Exchange
NASDAQ
Ticker Symbol
MITO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for MITO stock is "Buy." The 12-month stock price forecast is 3.12, which is an increase of 81.40% from the latest price.

Price Target
$3.12
(81.40% upside)
Analyst Consensus: Buy